The European Journal of Health Economics最新文献_第3页

How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review. 英国公众对社会经济群体之间的健康不平等有多反感?系统回顾。

The European Journal of Health Economics Pub Date : 2020-03-01 Epub Date: 2019-10-24 DOI: 10.1007/s10198-019-01126-2

Simon McNamara, John Holmes, Abigail K Stevely, Aki Tsuchiya

{"title":"How averse are the UK general public to inequalities in health between socioeconomic groups? A systematic review.","authors":"Simon McNamara, John Holmes, Abigail K Stevely, Aki Tsuchiya","doi":"10.1007/s10198-019-01126-2","DOIUrl":"10.1007/s10198-019-01126-2","url":null,"abstract":"There is growing interest in the use of \"distributionally-sensitive\" forms of economic evaluation that capture both the impact of an intervention upon average population health and the distribution of that health amongst the population. This review aims to inform the conduct of distributionally sensitive evaluations in the UK by answering three questions: (1) How averse are the UK public towards inequalities in lifetime health between socioeconomic groups? (2) Does this aversion differ depending upon the type of health under consideration? (3) Are the UK public as averse to inequalities in health between socioeconomic groups as they are to inequalities in health between neutrally framed groups? EMBASE, MEDLINE, EconLit, and SSCI were searched for stated preference studies relevant to these questions in October 2017. Of the 2155 potentially relevant papers identified, 15 met the predefined hierarchical eligibility criteria. Seven elicited aversion to inequalities in health between socioeconomic groups, and eight elicited aversion between neutrally labelled groups. We find general, although not universal, evidence for aversion to inequalities in lifetime health between socioeconomic groups, albeit with significant variation in the strength of that preference across studies. Second, limited evidence regarding the impact of the type of health upon aversion. Third, some evidence that the UK public are more averse to inequalities in lifetime health when those inequalities are presented in the context of socioeconomic inequality than when presented in isolation.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10198-019-01126-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73932991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. 使用注册数据对卡非佐米联合来那度胺和地塞米松治疗复发性多发性骨髓瘤的实际成本效益进行方法学和结果分析。

The European Journal of Health Economics Pub Date : 2020-03-01 Epub Date: 2019-10-31 DOI: 10.1007/s10198-019-01122-6

M Campioni, I Agirrezabal, R Hajek, J Minarik, L Pour, I Spicka, S Gonzalez-McQuire, P Jandova, V Maisnar

{"title":"Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.","authors":"M Campioni, I Agirrezabal, R Hajek, J Minarik, L Pour, I Spicka, S Gonzalez-McQuire, P Jandova, V Maisnar","doi":"10.1007/s10198-019-01122-6","DOIUrl":"10.1007/s10198-019-01122-6","url":null,"abstract":"Objective: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies.Methods: A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources.Results: The base case incremental cost effectiveness ratio for KRd compared with Rd was €73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of €117,534 over their lifetime compared with €53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively.Conclusions: Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10198-019-01122-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74866398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. 对携带表皮生长因子受体突变的非小细胞肺癌患者的一线表皮生长因子受体-TKIs进行成本效益分析。

The European Journal of Health Economics Pub Date : 2020-02-01 Epub Date: 2019-09-20 DOI: 10.1007/s10198-019-01117-3

Marscha S Holleman, Maiwenn J Al, Remziye Zaim, Harry J M Groen, Carin A Uyl-de Groot

{"title":"Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.","authors":"Marscha S Holleman, Maiwenn J Al, Remziye Zaim, Harry J M Groen, Carin A Uyl-de Groot","doi":"10.1007/s10198-019-01117-3","DOIUrl":"10.1007/s10198-019-01117-3","url":null,"abstract":"Objectives: To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.Methods: A systematic review and network meta-analysis (NMA) were conducted to compare the relative efficacy of gefitinib, erlotinib, afatinib, and osimertinib in EGFR-mutated NSCLC. To assess the cost-effectiveness of these treatments, a Markov model was developed from Dutch societal perspective. The model was based on the clinical studies included in the NMA. Incremental costs per life-year (LY) and per quality-adjusted life-year (QALY) gained were estimated. Deterministic and probabilistic sensitivity analyses (PSA) were conducted.Results: Total discounted per patient costs for gefitinib, erlotinib, afatinib, and osimertinib were €65,889, €64,035, €69,418, and €131,997, and mean QALYs were 1.36, 1.39, 1.52, and 2.01 per patient, respectively. Erlotinib dominated gefitinib. Afatinib versus erlotinib yielded incremental costs of €27,058/LY and €41,504/QALY gained. Osimertinib resulted in €91,726/LY and €128,343/QALY gained compared to afatinib. PSA showed that gefitinib, erlotinib, afatinib, and osimertinib had 13%, 19%, 43%, and 26% probability to be cost-effective at a threshold of €80,000/QALY. A price reduction of osimertinib of 30% is required for osimertinib to be cost-effective at a threshold of €80,000/QALY.Conclusions: Osimertinib has a better effectiveness compared to all other TKIs. However, at a Dutch threshold of €80,000/QALY, osimertinib appears not to be cost-effective.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75001462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does external reference pricing deliver what it promises? Evidence on its impact at national level. 外部参考定价是否兑现了承诺？关于其在国家层面影响的证据。

The European Journal of Health Economics Pub Date : 2020-02-01 Epub Date: 2019-10-03 DOI: 10.1007/s10198-019-01116-4

Panos Kanavos, Anna-Maria Fontrier, Jennifer Gill, Olina Efthymiadou

{"title":"Does external reference pricing deliver what it promises? Evidence on its impact at national level.","authors":"Panos Kanavos, Anna-Maria Fontrier, Jennifer Gill, Olina Efthymiadou","doi":"10.1007/s10198-019-01116-4","DOIUrl":"10.1007/s10198-019-01116-4","url":null,"abstract":"Background: External reference pricing (ERP) is widely used to regulate pharmaceutical prices and help determine reimbursement. Its implementation varies substantially across countries, making it difficult to study and understand its impact on key policy objectives.Objectives: To assess the evidence on ERP in different settings and its impact on key health policy objectives, notably, cost-containment, pharmaceutical price levels, drug use, equity, efficiency, availability, affordability and industrial policy; and second, to critically assess the quality of evidence on ERP.Methods: Primary and secondary data collection through a survey of leading experts and a systematic literature review, respectively, over the 2000-2017 period.Results: Forty five studies were included in the systematic review (January 2000-December 2016). Primary evidence was gathered via survey distribution to experts in 21 countries (January-July 2017). ERP contributes to cost-containment, but this is a short-term effect highly dependent on the way ERP is designed and implemented. Low prices, as a result of ERP, can undermine the availability of medicines and lead to launch delays or product withdrawals. Downward price convergence can hamper investment in innovation. ERP does not seem to promote efficiency in achieving health system goals. As evidence is weak, results need to be interpreted with caution.Conclusions: ERP has not regulated prices efficiently and has unintended consequences that reduce the benefits arising from it. If ERP is carefully designed with minimal price revisions, prudent selection of basket size and countries, and consideration of transaction prices, it could be a more effective mechanism enhancing welfare, equitable access to medicines within countries and help promote industry innovation.","PeriodicalId":22450,"journal":{"name":"The European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77372850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-compensatory aggregation method to measure social and material deprivation in an urban area: relationship with premature mortality 衡量城市地区社会和物质剥夺的非补偿性汇总方法:与过早死亡的关系

The European Journal of Health Economics Pub Date : 2019-12-06 DOI: 10.1007/s10198-019-01139-x

Carolina Bruzzi, Enrico Ivaldi, S. Landi

引用次数: 15

Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma 更正:在西班牙，糠酸氟替卡松/维兰特罗用于哮喘治疗的成本-后果分析:基于哮喘索尔福德肺部研究的分析

The European Journal of Health Economics Pub Date : 2019-12-04 DOI: 10.1007/s10198-019-01137-z

L. Vallejo-Aparicio, J. Molina, I. Ojanguren, A. Viejo Casas, A. Huerta, H. Svedsater

引用次数: 0

The societal monetary value of a QALY associated with EQ-5D-3L health gains 与EQ-5D-3L健康收益相关的QALY的社会货币价值

The European Journal of Health Economics Pub Date : 2019-11-28 DOI: 10.1007/s10198-019-01140-4

L. Vallejo-Torres, B. García-Lorenzo, O. Rivero-Arias, J. Pinto-Prades

引用次数: 8

Economic evaluation of meningococcal vaccines: considerations for the future 脑膜炎球菌疫苗的经济评价:对未来的考虑

The European Journal of Health Economics Pub Date : 2019-11-21 DOI: 10.1007/s10198-019-01129-z

H. Christensen, H. Al-Janabi, P. Levy, M. Postma, D. Bloom, Paolo Landa, O. Damm, D. Salisbury, J. Díez-Domingo, A. Towse, P. Lorgelly, K. Shah, K. Hernandez-villafuerte, Vinny Smith, L. Glennie, C. Wright, L. York, R. Farkouh

引用次数: 23

Unfolding the relationship between mortality, economic fluctuations, and health in Italy 揭示意大利死亡率、经济波动和健康之间的关系

The European Journal of Health Economics Pub Date : 2019-11-20 DOI: 10.1007/s10198-019-01135-1

Maddalena Cavicchioli, B. Pistoresi

引用次数: 6

Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy Neuropad装置作为早期糖尿病周围神经病变筛查工具的成本-效果分析

The European Journal of Health Economics Pub Date : 2019-11-12 DOI: 10.1007/s10198-019-01134-2

B. Rodríguez-Sánchez, L. M. Peña-Longobardo, A. Sinclair

引用次数: 5